 President's Message |
| Since the recent publication of the discovery of induced pluripotent stem (iPS) cells, the concept of regenerative therapy has changed dramatically. The concept has evolved to become more sophisticated, to the extent that regenerative therapy is no longer considered supplementary therapy, but is now considered to be part of mainstream medicine, used for activation of the human immune system. Importantly, therapy that aims to enhance the potential regenerative functions of humans can be expected to cause fewer side effects than one that introduces a “foreign objectEinto the body, which may result in a hypersensitivity reaction.
|
President/CEO
Kunio Iwatani
|
|
Kringle Pharma is a biotech venture company that was spun-off from Osaka University. Its mission is to research hepatocyte growth factor (HGF), an intrinsic factor with an organotrophic role in the regeneration and repair of various tissues and organs, and to use this research to develop treatments for incurable diseases. Kringle Pharma was founded in 2001, since which time it has been steadily growing. We still remain compact in size, but are pursuing dream to provide novel therapeutics for unmet medical needs. Kringle Pharma has been fortunate enough to receive generous support from our business partners, enabling us to move closer to our dream, including the establishment of a manufacturing system for GMP-grade recombinant human HGF, as well as initiating clinical studies in the United States and Sweden.
Another drug candidate waiting in our R&D pipeline is NK4, an antagonist of HGF and a multi-target angiogenesis inhibitor, as a cancer therapeutic. Kringle Pharma’s ultimate goal is to provide solutions for patients all over the world who are suffering from severe diseases through the clinical development of products based on HGF and NK4. To help us make this dream come true, I look forward to your continuous support for our efforts at Kringle Pharma.
|
Origin of Company Name
Kringle Pharma, Inc.
|
NK4 :
NK4, the molecule that displays antagonistic activity to HGF (hepatocyte growth factor), derives its name from its 4 kringle structures next to the N-terminal hairpin structure.
Company Name :
Both HGF and NK4 have kringle structures at the active site of the molecule. Therefore, we named the company name "Kringle Pharma, Inc." after "Kringle" and "Pharmaceuticals".
Principal Project :
The main goal for Kringle Pharma, Inc. is to develop pharmaceutical products based on our research on HGF and NK4. Our corporate mission is ultimately to save patients suffering from cancer or other diseases in the world by improving the quality of their life.
|
|
